Baylor Genetics delivers the future of precision diagnostics through comprehensive genetic testing and genomic analysis. For nearly 50 years, the organization has pioneered advances in genetic testing, driving innovation from the first chromosomal microarray and whole exome sequencing to today's cutting-edge whole genome sequencing and multiomics approaches. As a joint venture between Baylor College of Medicine and HU Group Holdings, Inc., Baylor Genetics combines clinical excellence with scalable infrastructure to provide clinically relevant diagnostic insights across rare diseases, pediatric genetics, reproductive health, hereditary cancer, and metabolic disorders.
The company's diagnostic genomics platform offers a full spectrum of tests including Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Chromosomal Microarray Analysis, and specialized assays. Each result is interpreted by a world-class team of PhDs, MDs, laboratory directors, and genetic counselors who translate complex genomic data into clear, actionable insights. With over 4 million tests performed worldwide and accreditation from CLIA, CAP, and New York State Department of Health, Baylor Genetics empowers patients, healthcare providers, and partners with trusted answers that transform complex genomic data into informed clinical decisions.